Lifeng Huang

Nov 12, 2024 | bmccancer.biomedcentral.com | Yinggang Xu |Lifeng Huang |Jue Wang |Jinzhi He |Ye Wang |Weiwei Zhang | +7 more

Based on previous studies, the incidence of grade 3–4 neutropenia for the control group was assumed to be 40%, and we hypothesized that the incidence in the experimental group would be halved to 20%. Using a two-sided significance level (α) of 0.05 and a power of 80%, the calculated sample size for each group was 79 patients. Given the short duration of the study, we anticipate a low rate of loss to follow-up.